BioSig Technologies Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat BioSig Technologies de winst en omzet met respectievelijk 15.6% en 225.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 36.8% per jaar.

Belangrijke informatie

15.6%

Groei van de winst

36.8%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	225.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	12 Sep 2024

Recente toekomstige groei-updates

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

Winst- en omzetgroeiprognoses

NasdaqCM:BSGM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	1	-12	N/A	-8	1
12/31/2024	N/A	-14	N/A	-7	1
9/30/2024	0	-15	-7	-7	N/A
6/30/2024	0	-18	-10	-10	N/A
3/31/2024	0	-25	-13	-13	N/A
12/31/2023	0	-29	-17	-17	N/A
9/30/2023	0	-30	-19	-18	N/A
6/30/2023	0	-32	-20	-20	N/A
3/31/2023	0	-27	-22	-21	N/A
12/31/2022	0	-27	-22	-22	N/A
9/30/2022	0	-29	-24	-23	N/A
6/30/2022	0	-30	-26	-25	N/A
3/31/2022	0	-32	-26	-25	N/A
12/31/2021	0	-32	-27	-26	N/A
9/30/2021	0	-34	-27	-27	N/A
6/30/2021	0	-38	-27	-26	N/A
3/31/2021	0	-49	-28	-28	N/A
12/31/2020	N/A	-52	-27	-27	N/A
9/30/2020	N/A	-57	-25	-24	N/A
6/30/2020	N/A	-51	-22	-22	N/A
3/31/2020	N/A	-40	-18	-18	N/A
12/31/2019	N/A	-34	-16	-15	N/A
9/30/2019	N/A	-25	-15	-15	N/A
6/30/2019	N/A	-23	-13	-13	N/A
3/31/2019	N/A	-21	-12	-11	N/A
12/31/2018	N/A	-18	-11	-10	N/A
9/30/2018	N/A	-17	-10	-10	N/A
6/30/2018	N/A	-15	N/A	-9	N/A
3/31/2018	N/A	-12	N/A	-8	N/A
12/31/2017	N/A	-13	N/A	-7	N/A
9/30/2017	N/A	-10	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-6	N/A
3/31/2017	N/A	-12	N/A	-6	N/A
12/31/2016	N/A	-12	N/A	-5	N/A
9/30/2016	N/A	-12	N/A	-5	N/A
6/30/2016	N/A	-11	N/A	-5	N/A
3/31/2016	N/A	-9	N/A	-4	N/A
12/31/2015	N/A	-10	N/A	-5	N/A
9/30/2015	N/A	-10	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-11	N/A	-3	N/A
12/31/2014	N/A	-9	N/A	-2	N/A
9/30/2014	N/A	-8	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat BSGM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat BSGM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat BSGM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van BSGM ( 225.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van BSGM ( 225.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van BSGM naar verwachting over 3 jaar hoog zal zijn

BioSig Technologies Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 67%, EPS upgraded

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

Consensus revenue estimates decrease by 65%, EPS upgraded

Recent updates

BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024

BioSig Technologies' Common Stock Deleted from OTC Equity

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven